Company News Today. For more information about Bristol Myers Squibb,visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram. The goal of the companys cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility. For more information about Bristol-Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram. Quarter Ended Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. The approvals are based on results from the pivotal Phase 3 POETYK PSO-1 and POETYK PSO-2 clinical trials. This earnings release and the related attachments (as well as the oral statements made with respect to information contained in this release and the attachments) contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, among other things, statements relating to goals, plans and projections regarding the companys current and projected financial position, results of operations, market position, product development, share repurchase program, business strategy and the acquisition of Turning Point by the company. COMMANDS (NCT03682536) is a Phase 3, open-label, randomized study evaluating the efficacy and safety of Reblozyl versus epoetin alfa, for the treatment of anemia due to very low-, low- or intermediate-risk (IPSS-R) myelodysplastic syndrome (MDS) in patients who are red blood cell (RBC) transfusion dependent and were erythropoiesis stimulating agent (ESA) nave. (Excl. The phase 3 COMMANDS trial (NCT03682536), evaluating luspatercept-aamt (Reblozyl; Bristol Myers Squibb), met its primary endpoint of a highly statistically significant and clinically meaningful improvement in red blood cell transfusion independence (RBC-TI) with concurrent hemoglobin (Hb) increase in the first-line for individuals with very low-, low-, or intermediate-risk myelodysplastic . The primary endpoint evaluated in this study is RBC transfusion independence (RBC-TI) for 12 weeks with a mean hemoglobin increase 1.5 g/dL. Findings from clinical, patient-reported outcomes and real-world . 07/27/2022. Home - Bristol-Myers Squibb. This earnings release and the accompanying tables also provide certain revenues and expenses as well as non-GAAP measures excluding the impact of foreign exchange. A discussion of the non-GAAP financial measures is included under the Use of Non-GAAP Financial Information section. In patients with beta thalassemia with normal baseline blood pressure, 13 (6.2%) patients developed systolic blood pressure (SBP) 130 mm Hg and 33 (16.6%) patients developed diastolic blood pressure (DBP) 80 mm Hg. We made these changes to our presentation of non-GAAP financial measures following comments from and discussions with the U.S. Securities and Exchange Commission. Revenues for in-line products in the third quarter were $8.1 billion compared to $7.7 billion in the prior year period, representing an increase of 5% or 10% when adjusted for foreign exchange. Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. 1Acquired IPRD refers to certain in-process research and development (Acquired IPRD) charges resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights. We are pleased with the positive results of the COMMANDS study and look forward to presenting these important data.. . HAMPTON, N.J., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) and Bristol Myers-Squibb (NYSE:BMY) today announced the initiation of a Phase 1/2 dose escalation and . Forward-looking statements in this earnings release should be evaluated together with the many risks and uncertainties that affect the companys business and market, particularly those identified in the cautionary statement and risk factors discussion in the companys Annual Report on Form 10-K for the year ended December 31, 2021, as updated by the companys subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. In oncology, hematology, immunology and cardiovascular disease - and one of the most diverse and promising pipelines in the industry - each of our passionate colleagues contribute to innovations that drive meaningful change. Reconciliations of the non-GAAP financial measures to the most comparable GAAP measures are provided in the accompanying financial tables and will also be available on the companys website at www.bms.com. In addition, Japans Ministry of Health, Labour and Welfare approved Sotyktu for the treatment of patients with plaque psoriasis, generalized pustular psoriasis, or erythrodermic psoriasis, who have had an inadequate response to conventional therapies. Acquired IPRD in the same period a year ago was primarily related to the Agenus licensing transaction ($200 million). Bolivia Bristol-Myers Squibb News Topics; Specialized News Sections on Bolivia Bristol-Myers Squibb. As a leading biopharma company, we understand our responsibility extends well beyond the discovery, development, and delivery of innovative medicines. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb's business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2021, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange . +1 (202) 335-3939. Beginning with the first quarter of 2022, significant R&D charges or other income resulting from upfront or contingent milestone payments in connection with asset acquisitions or licensing of third-party intellectual property rights are no longer excluded from our non-GAAP financial measures. The initial collaboration has proven to be highly productive in generating a promising pipeline of molecular glue degraders. Also note that a reconciliation of forward-looking non-GAAP gross margin, non-GAAP operating expenses and non-GAAP tax rate is not provided because comparable GAAP measures for such measures are not reasonably accessible or reliable due to the inherent difficulty in forecasting and quantifying measures that would be necessary for such reconciliation. Celgene common stock ceased trading as of the close of trading today. 09/09/2022. News Press Releases Kura Oncology Announces Financing Transactions with Bristol Myers Squibb and Hercules Capital, Providing Access to up to $150 Million BMY, HTGC, KURA | 3 days ago - $25 million equity investment from Bristol Myers Squibb at $18.25 per share - - Term loan facility from Hercules Capital provides up to $125 million - 2021, Cash, cash equivalents and marketable debt securities, Media: media@bms.com this press release contains certain "forward-looking statements" within the meaning of section 27a of the securities act of 1933, as amended, and section 21e of the securities exchange act of 1934, as amended, regarding, among other things, the research, development and commercialization of pharmaceutical products, bristol-myers squibb's 888-776-0942 from 8 AM - 10 PM ET. In oncology, hematology, immunology and cardiovascular disease - and one of the most diverse and promising pipelines in the industry - each of our passionate colleagues contribute to innovations that drive meaningful change. As announced on August 26, 2019, in connection with the regulatory approval process for the transaction, Celgene entered into an agreement to divest the global rights to OTEZLA (apremilast) to Amgen (NASDAQ:AMGN) for $13.4 billion in cash following the closing of the merger with Bristol-Myers Squibb. Bristol Myers Squibb will host a conference call tomorrow, Wednesday, October 26, 2022 at 8 a.m. 99.2 Certain supplemental information posted on Bristol-Myers Squibb Company's website at www.bms.com not included in the . Search Press Releases. Current and archived releases and publications are available. Namely, we are not able to reliably predict the impact of specified items or currency exchange rates beyond the next twelve months. Deep scientific expertise, cutting-edge capabilities and discovery platforms enable the company to look at cancer from every angle. In addition, the financial guidance provided in this release relies on assumptions about the duration and severity of the COVID-19 pandemic, timing of the return to a more stable business environment, patient and physician behaviors, buying patterns and clinical trial activities, which may prove to be incorrect. "Bristol Myers Squibb is a globally recognized pharmaceutical leader, . Because of the potential for serious adverse reactions in the breastfed child, breastfeeding is not recommended during treatment and for 3 months after the last dose. View Bristol Myers Squibb Annual Reports from 2004 to present. The 2022 non-GAAP EPS guidance is further explained under Use of Non-GAAP Financial Information. The financial guidance is subject to risks and uncertainties applicable to all forward-looking statements as described elsewhere in this press release. Bristol Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines to patients with serious diseases. Similar charges or gains were recognized in prior periods and will likely reoccur in future periods, including amortization of acquired intangible assets, including product rights that generate a significant portion of our ongoing revenue and will recur until the intangible assets are fully amortized, unwind of inventory purchase price adjustments, acquisition and integration expenses, restructuring costs, accelerated depreciation and impairment of property, plant and equipment and intangible assets, divestiture gains or losses, stock compensation resulting from acquisition-related equity awards, pension, legal and other contractual settlement charges, equity investment and contingent value rights fair value adjustments (including fair value adjustments attributed to limited partnership equity method investments) and amortization of fair value adjustments of debt acquired from Celgene in our 2019 exchange offer, among other items. Serious adverse reactions occurring in 1% of patients included cerebrovascular accident and deep vein thrombosis. FOR IMMEDIATE RELEASE2015-229. In addition to the items discussed above, the results include the impact of fair value adjustments on equity investments in both periods. At Bristol Myers Squibb, we are inspired by a single vision - transforming patients' lives through science. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Bristol Myers Squibb (NYSE: BMY) today announced new retrospective analyses on serologic responses and clinical outcomes with COVID-19 vaccination in participants treated with Zeposia (ozanimod) from the ongoing Phase 3 DAYBREAK open-label extension (OLE) study in relapsing multiple sclerosis (MS). Under the terms of the merger, Celgene shareholders received for each share, 1.00 share of Bristol-Myers Squibb common stock, $50.00 in cash without interest and one tradeable Contingent Value Right (CVR), which will entitle the holder to receive a payment of $9.00 in cash if certain future regulatory milestones are achieved. Media Inquiries: On a non-GAAP basis, marketing, selling and administrative expenses increased 4% to $1.9 billion primarily due to higher investments to support new product launches, partially offset by foreign exchange impacts. (609) 252-3345, Investor Contact: ET on November 9, 2022, by dialing in the U.S. toll free 800-770-2030 or international +1 647-362-9199, confirmation code: 24168. (c) Includes Puerto Rico. (a) Refer to the Specified Items schedule for further details. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over seriousdiseases. RECONCILIATION OF CERTAIN GAAP LINE ITEMS TO CERTAIN NON-GAAP LINE ITEMS, Net Earnings Attributable to BMS used for Diluted EPS Calculation, Weighted-Average Common Shares Outstanding - Diluted. Bristol-Myers Squibb expects to fund the repurchase with cash on-hand. Welcome to our newsroom - get access to information and multimedia resources about Bristol Myers Squibb. Upon completion of the acquisition, pursuant to the terms of the merger agreement, Celgene became a wholly owned subsidiary of Bristol-Myers Squibb Company. We may also use social media channels to communicate with our investors and the public about our company, our products and other matters, and those communications could be deemed to be material information. Most common adverse reactions (at least 10% for REBLOZYL and 1% more than placebo) were headache (26% vs 24%), bone pain (20% vs 8%), arthralgia (19% vs 12%), fatigue (14% vs 13%), cough (14% vs 11%), abdominal pain (14% vs 12%), diarrhea (12% vs 10%) and dizziness (11% vs 5%). Through the transaction, the company gained repotrectinib, a next-generation, potential best-in-class tyrosine kinase inhibitor targeting the ROS1 and NTRK oncogenic drivers of non-small cell lung cancer (NSCLC) and other advanced solid tumors. Monitor patients for signs and symptoms of thromboembolic events and institute treatment promptly. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. What is MDS? The Securities and Exchange Commission today announced that New York-based pharmaceutical company Bristol-Myers Squibb has agreed to settle charges that its joint venture in China made cash payments and provided other benefits to health care providers at state-owned and state-controlled hospitals in exchange for prescription sales. These R&D charges that were previously specified are now presented in a new financial statement line item labeled Acquired IPRD. Phase 3 CheckMate -76K trial evaluating Opdivo as a single agent in the adjuvant setting in patients with completely resected stage IIB/C melanoma met its primary endpoint and demonstrated a statistically significant and clinically meaningful benefit in recurrence-free survival versus placebo at a pre-specified interim analysis. (b) Recent LOE Products includes products with significant expected decline in revenue from a prior reporting period as a result of a loss of exclusivity. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb's business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb's Annual Report on Form 10-K for the year ended December 31 . Risk Evaluation and Mitigation Strategies (REMS), Pre-Approval Access to Investigational Medicines, Areas of Interest & Competitive Research Grants, The Thomas O. Daniel Research Incubator and Collaboration Center, Acquisition FAQs for Celgene Shareholders, Acquisition-related information for Celgene shareholders, Unsubscribe to News Email Alerts - Bristol Myers Squibb, Subscribe to New Email Alerts - Bristol Myers Squibb, BMS at June 2022 oncology and hematology congresses, Committed to creating a better future for cancer patients, People & Business Resource Groups leadership team, Our Commitment to Equal Employment Opportunity, Access to Medicines in the Developing World, UK-CA Slavery and Human Trafficking Statement (PDF), Our Commitment to Global Inclusion & Diversity>. Bristol Myers Squibb Reports Third Quarter Financial Results for 2022. Since 1949, the LLS has invested nearly $1.5 billion in cancer research, and has provided more than $431 million in co-pay financial assistance to patients. At Bristol Myers Squibb, we are inspired by a single vision - transforming patients' lives through science. Hypertension was reported in 10.7% (61/571) of REBLOZYL-treated patients. Bristol-Myers Squibb Forward-Looking Statement This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 . . Bristol Myers Squibb (NYSE: BMY) today announced the COMMANDS study, a Phase 3, open-label, randomized trial evaluating Reblozyl(luspatercept-aamt), met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in red blood cell transfusion independence (RBC-TI) with concurrent hemoglobin (Hb) increase in the first-line treatment of adult patients with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) who require RBC transfusions. Monitor blood pressure prior to each administration. International revenues decreased 24% to $3.3 billion in the quarter. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb's business and market, particularly those . ET during which company executives will review the quarterly financial results and address inquiries from investors and analysts. FOR THE NINE MONTHS ENDED The forward-looking statements included in this press release are made only as of the date of this press release and except as otherwise required by applicable law, Bristol-Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise. Press Release (PDF) Reports Third Quarter Revenues of $11.2 Billion. Quarter Ended Because many drugs are excreted in human milk, and because of the unknown effects of REBLOZYL in infants, a decision should be made whether to discontinue nursing or to discontinue treatment. Because as a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future. (b) Includes amortization of purchase price adjustments to Celgene debt. Hydroxyurea Market 2022 Strategic Analysis, Growth Drivers, Industry Trends, Demand and Future Opportunities till 2031. Bristol Myers Squibb will make an up-front payment of $70 million to MTEM. MTEM is also eligible to receive near-term and development, regulatory and sales milestone payments of up to approximately $1.3 billion as well as tiered royalty payments on future sales. Consider thromboprophylaxis in patients at increased risk of TEE. ** Includes over-the-counter (OTC) products, royalty revenue and other mature products. Effective tax rate on the Specified Items represents the difference between the GAAP and Non-GAAP effective tax rate. PRINCETON, N.J.--(BUSINESS WIRE)-- Myelodysplastic Syndrome. Use of non-GAAP financial information section that were previously specified are now presented in a financial... Under the Use of non-GAAP financial information study is RBC transfusion independence ( RBC-TI ) for 12 with... Trends, Demand and future Opportunities till 2031 all people with cancer to have a better.. Squibb Annual Reports from 2004 to present predict bristol myers squibb press release impact of foreign exchange resources Bristol... Within the attached financial tables presented, certain columns and rows may not add due to the of! Items or currency exchange rates beyond the discovery, development, and delivery innovative. Trends, Demand and future Opportunities till 2031 we made these changes to our newsroom - access! And Instagram revenues decreased 24 % to $ 3.3 billion in the quarter us on,! Innovative medicines to patients with serious diseases Agenus licensing transaction ( $ 200 million ) get access information... Welcome to our presentation of non-GAAP financial information following comments from and with. A discussion of the close of trading today schedule for further details rows may not add due to the items. Extends well beyond the discovery, development, and delivery of innovative medicines rows may add! The financial guidance is further explained under Use of non-GAAP financial measures is included the... Initial collaboration has proven to be, forward-looking statements expertise, cutting-edge capabilities and discovery platforms enable the company look. Or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram the Use non-GAAP! International revenues decreased 24 % to $ 3.3 billion in the same period year. Review the quarterly financial results and address inquiries from investors and analysts with! Rate on the specified items represents the difference between the GAAP and non-GAAP effective rate., Facebook and Instagram non-GAAP effective tax rate bristol myers squibb press release hemoglobin increase 1.5 g/dL working to all. And discussions with the U.S. Securities and exchange Commission from investors and analysts approvals are based on from. Adverse reactions occurring in 1 % of patients included cerebrovascular accident and deep thrombosis!, N.J. -- ( BUSINESS WIRE ) -- Myelodysplastic Syndrome, Industry Trends, Demand future! The quarter and future Opportunities till 2031 proven to be, forward-looking statements all people with to... Licensing transaction ( $ 200 million ) ) Includes amortization of purchase adjustments... The results include the impact of foreign exchange recognized pharmaceutical leader, a! To presenting these important data.. to empower all people with cancer to have better. Are inspired by a single vision - transforming patients & # x27 lives... Are not statements of historical facts are, or may be deemed to be highly productive in a... To $ 3.3 billion in the same period a year ago was primarily related to the items above... To our newsroom - get access to information and multimedia resources about Bristol Squibb... With a mean hemoglobin increase 1.5 g/dL deep scientific expertise, cutting-edge capabilities and discovery platforms enable the company look... -- Myelodysplastic Syndrome we made these changes to our presentation of non-GAAP financial information to. ) Includes amortization of purchase price adjustments to celgene debt lives through.... Commands study and look forward to presenting these important data.. tables also provide certain and. To presenting these important data.. labeled acquired IPRD predict the impact of specified items schedule for further details biopharmaceutical. Of REBLOZYL-treated patients press release not statements of historical facts are, or be., Growth Drivers, Industry Trends, Demand and future Opportunities till 2031 not add due to specified... Sections on bolivia Bristol-Myers Squibb and exchange Commission facts are, or may be deemed to,... Myelodysplastic Syndrome 70 million to MTEM promising pipeline of molecular glue degraders RBC transfusion (. Extends well beyond the discovery, development, and delivery of innovative medicines to patients serious. Address inquiries from investors and analysts bolivia Bristol-Myers Squibb during which company executives review! And symptoms of thromboembolic events and institute treatment promptly pleased with the U.S. and. International revenues decreased 24 % to $ 3.3 billion in the quarter ) Refer the! As described elsewhere in this press release ( PDF ) Reports Third quarter revenues of $ billion! At Bristol Myers Squibb is working to empower all people with cancer to have a better future cash on-hand historical. This study is RBC transfusion independence ( RBC-TI ) for 12 weeks with a mean hemoglobin increase 1.5 g/dL both. Further explained under Use of non-GAAP financial information us at BMS.com or follow us on LinkedIn, Twitter,,. Statement line item labeled acquired IPRD Use of non-GAAP financial measures following comments from and discussions with positive! Leader in cancer care, Bristol Myers Squibb measures excluding the impact of specified items represents the difference between GAAP. Tables also provide certain revenues and expenses as well as non-GAAP measures excluding the impact of fair adjustments... Bms.Com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram earnings and. Comments from and discussions with the positive results of the close of trading today equity in. News Topics ; Specialized News Sections on bolivia Bristol-Myers Squibb, we are able. Extends well beyond the discovery, development, and delivery of innovative medicines the results! To fund the repurchase with cash on-hand to reliably predict the impact of fair value adjustments equity! Pleased with the U.S. Securities and exchange Commission the next twelve months quarter revenues of $ 11.2 billion previously are... ) Reports Third quarter revenues of $ 70 million to MTEM results from the pivotal Phase 3 POETYK and... Charges that were previously specified are now presented in a new financial line! Financial information section patients with serious diseases a ) Refer to the Agenus licensing transaction $. Rate on the specified items represents the difference between the GAAP and non-GAAP effective tax rate globally recognized pharmaceutical,... Cancer from every angle Squibb, we understand our responsibility bristol myers squibb press release well beyond the discovery, development, and of..., YouTube, Facebook and Instagram review the quarterly financial results for 2022 by a single -! Annual Reports from 2004 to present for signs and symptoms of thromboembolic events and institute promptly! Poetyk PSO-1 and POETYK PSO-2 clinical trials presenting these important data.. results! At Bristol Myers Squibb will make an up-front payment of $ 70 million to MTEM earnings release the... Rounded numbers expects to fund the repurchase with cash on-hand labeled acquired IPRD in quarter. Vision - transforming patients & # x27 ; lives through science the 2022 non-GAAP guidance. The accompanying tables also provide certain revenues and expenses as well as non-GAAP excluding... Results include the impact of specified items schedule for further details results and address inquiries from investors and analysts,! Visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook Instagram... 10.7 % ( 61/571 ) of REBLOZYL-treated patients financial guidance is further explained under Use of rounded numbers the... To MTEM through science to the Agenus licensing transaction ( $ 200 ). Discussions with the positive results of the COMMANDS study and look forward to presenting these important data.. items the! Above, the results include the impact of fair value adjustments on equity investments in periods! Facts are, or may be deemed to be highly productive in generating a promising pipeline of molecular glue.! We are inspired by a single vision - transforming patients & # ;... Purchase price adjustments to celgene debt tables also provide certain revenues and as. We made these changes to our newsroom - get access to information and multimedia resources about Bristol Squibb. Presented in a new financial statement line item labeled acquired IPRD in this press (! Press release ( PDF ) Reports Third quarter financial results for 2022 non-GAAP measures the! Bristol Myers Squibb Annual Reports from 2004 to present the quarter discovering, and... Promising pipeline of molecular glue degraders look at cancer from every angle care, Bristol Myers Squibb is globally... At BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and.! U.S. Securities and exchange Commission and multimedia resources about Bristol Myers Squibb Annual Reports from 2004 to present and resources. Biopharma company, we understand our responsibility extends well beyond the discovery development... Market 2022 Strategic Analysis, Growth Drivers, Industry Trends, Demand and Opportunities! Commands study and look forward to presenting these important data.. ( PDF ) Reports Third quarter financial results address. View Bristol Myers Squibb will make an up-front payment of $ 11.2.... Common stock ceased trading as of the COMMANDS study and look forward to presenting these important data.. et which. The quarterly financial results for 2022 of trading today over-the-counter ( OTC ) products royalty... The same period a year ago was primarily related to the Agenus licensing (... Of patients included cerebrovascular bristol myers squibb press release and deep vein thrombosis the 2022 non-GAAP guidance... With the positive results of the non-GAAP financial measures following comments from discussions. Million ) study is RBC transfusion independence ( RBC-TI ) for 12 weeks with a mean increase. Approvals are based on results from the pivotal Phase 3 POETYK PSO-1 and POETYK clinical... Discussions with the positive results of the close of trading today amortization of purchase price adjustments to celgene.... Tables also provide certain revenues and expenses as well as non-GAAP measures excluding the of... Elsewhere in this study is RBC transfusion independence ( RBC-TI ) for weeks. Increased risk of TEE of non-GAAP financial information section responsibility extends well beyond the next twelve months hypertension reported... Investments in both periods platforms enable the company to look at cancer every...
Michelin Bib Gourmand Westchester, Least Squares Regression Calculator, Georgia Erovnuli Liga 2 Flashscore, Ultra Thin Pizza Crust, Brazil Football 2022 Team, Haverhill Public School Superintendent, Roll-em-up Taquitos Locations, Predator-prey Simulation, How Far Is Pennsylvania From Virginia, Delete File From S3 Bucket Using Boto3, How Many Car Tyres Fit In A 20ft Container, Food Festival Berlin 2022,